* Mipomersen sodium (Kynamro) is a new subcutaneous weekly injection approved for the treatment of homozygous familial hypercholesterolemia, an inherited condition that prevents the body from removing low-density lipoprotein cholesterol from the bloodstream.
* The drug is not to be used as monotherapy, but rather in conjunction with other lipid-lowering drugs and diet restrictions.
* Mipomersen sodium raises the risk of hepatotoxicity. Injection-site reactions and flulike symptoms are among the most common adverse effects.